25 release. Gilead has an array of HIV drugs on the market, which brought in a combined $5.1 billion in sales in the third ...

This article explores the difficulties faced in attempting to treat HIV, an innovative prevention strategy and the ...

Such laws were passed in the early days of the AIDS epidemic, before the advent of highly effective antiviral drugs, which ...

DALLAS, TX / ACCESSWIRE / November 19, 2024 / Adnexus Biotechnologies Inc. is pleased to announce the appointment of Dr. Hiroshi Ohrui to its Scientific Advisory Board. Dr. Ohrui is a distinguished ...

Business which accounts for close to one-third of group sales also took in €437m in dividends from subsidiaries dotted ...

AMR is a pressing global concern, diminishing the effectiveness of antimicrobial drugs and threatening public health and ...

SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Press Release - A drug currently approved for smallpox in the U.S. will undergo clinical trials to treat patients infected by the Mpox viruswho are at risk of severe complications in the Democratic ...